MedPath

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

Completed
Conditions
Cutaneous Malignant Melanoma
Interventions
Procedure: Biopsy
Registration Number
NCT01482260
Lead Sponsor
Ruhr University of Bochum
Brief Summary

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

Detailed Description

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). With regards to a rapidly growing number of newly discovered miRNA sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign melanocytic naevi (BMN) is limited. Patients with PCMM, CMMM and BMN are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • Primary Cutaneous Malignant Melanoma
  • Cutaneous Malignant Melanoma Metastases
  • Benign Melanocytic Naevi
Exclusion Criteria
  • Other Skin Cancer than Primary Cutaneous Malignant Melanoma

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Benign Melanocytic NeviBiopsy-
Primary Cutaneous Malignant MelanomaBiopsy-
Cutaneous Malignant Melanoma MetastasesBiopsy-
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum

🇩🇪

Bochum, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath